KR
Krebs Biochemicals & Industries Ltd (KREBSBIO)
₹59.46
Mkt cap
₹124 Cr
P/E ratio
—
P/B
−0.79
Div yield
0.00%
ROE
—
ROCE
−15.40%
EPS (TTM)
—
Book value
−₹76
52W range
38–77
Sector
Healthcare
Price history
Previous close
Incorporated in 1991, Krebs Biochemicals & Industries Ltd is presently engaged in manufacturing of active pharmaceutical ingredients.
NSE KREBSBIOBSE 524518
Health check
Mixed
ProfitabilityWeak
GrowthHigh
TechnicalsNeutral
52-week range
−22.63% from high₹59
₹38+55.13% from low₹77
Current
₹59.46
Prev close
₹64.00
Day
−7.09%
Price performance
1D
−7.09%
1W
+3.27%
1M
+9.10%
3M
+2.20%
6M
+24.84%
1Y
−16.31%
YTD
−16.22%
Financials
Revenue, profit & margin
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.58 | 14.89 | 12.98 | 11.97 | 12.89 | 12.86 | 11.47 | 6.10 | 5.48 | 4.17 | 7.27 | 6.81 | 6.98 | |
| Expenses | 13.20 | 15.79 | 15.07 | 15.09 | 15.08 | 15.58 | 16.18 | 11.51 | 7.57 | 6.97 | 6.97 | 7.67 | 6.16 | |
| Operating Profit | -2.62 | -0.90 | -2.09 | -3.12 | -2.19 | -2.72 | -4.71 | -5.41 | -2.09 | -2.80 | 0.30 | -0.86 | 0.82 | |
| OPM % | -24.76% | -6.04% | -16.10% | -26.07% | -16.99% | -21.15% | -41.06% | -88.69% | -38.14% | -67.15% | 4.13% | -12.63% | 11.75% | |
| Other Income | 0.04 | 0.17 | 0.03 | 0.21 | 0.03 | 0.09 | 0.25 | 0.34 | 0.01 | 0.01 | 0.00 | 2.00 | 0.16 | |
| Interest | 1.10 | 1.13 | 1.19 | 1.27 | 1.32 | 1.42 | 1.56 | 1.61 | 1.65 | 1.73 | 1.79 | 1.91 | 1.88 | |
| Depreciation | 1.65 | 1.71 | 1.73 | 1.67 | 1.69 | 1.71 | 1.72 | 1.57 | 1.60 | 1.62 | 1.63 | 1.57 | 1.59 | |
| Profit before tax | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.25 | -5.33 | -6.14 | -3.12 | -2.34 | -2.49 | |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| Net Profit | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.27 | -5.32 | -6.14 | -3.13 | -2.34 | -2.48 | |
| EPS in Rs | -2.47 | -1.66 | -2.31 | -2.71 | -2.40 | -2.67 | -3.59 | -3.84 | -2.47 | -2.85 | -1.45 | -1.09 | -1.15 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.97% · closed higher next day 1 of last 1
| Q1FY27† | |
|---|---|
| Broadcast | 6 Aug '26 |
| Earnings day | +0.97% |
| +1 day | +4.99% |
| +5 days | +0.17% |
| +15 days | +8.55% |
| +30 days | +3.14% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202672.74%Promoter
Promoters72.74%
FIIs0.50%
Public26.76%
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Krebs Biochem | ₹57.31 | — | 124 | 0.00% | −2 | +53.38% | 7 | +27.37% | −15.37% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Sep - Company has enclosed herewith copy of Newspaper Advertiesment of the Notice issued to shareholders wrt 34th AGM.Notice Of 34Th Annual General Meeting Of The Company 4 SepReg. 34 (1) Annual Report. 4 Sep - Krebs Biochemicals filed FY26 annual report and AGM notice for 29 Sep 2026, including RPT approval up to ₹120 crore.Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Sep - Company has enclosed herewith copy of newspaper advertiesment w.r.t. prior intimation of 34th AGM of the Company.Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Aug - Company has enclosed herewith copy of newpapers advertiesment of unaudited financial results for the quarter ended 30.06.2026